Aytu BioScience
Mr. Selhorn has served as the Executive Vice President, Finance and Business Optimization since November 2022. Prior to this, Mr. Selhorn served as the Senior Vice President, Finance & Operations, Consumer Healthcare Division from February 2022 to November 2022 and as the Vice President, Finance, Consumer Healthcare Division from February 2020 to February 2022. Mr. Selhorn served as Vice President & Chief Financial Officer from April 2018 at Innovus Pharmaceuticals, Inc., a publicly held consumer healthcare company, until Aytu’s acquisition of Innovus in February 2020. From August 2013 to April 2018, Mr. Selhorn served as Chief Financial Officer and Chief Accounting Officer of Signature Analytics, a privately held fractional CFO and accounting firm, where he also served as Chief Financial Officer of Medicinova Inc, a publicly held biotechnology company, assisted Dare Bioscience, Inc. to complete a reverse merger into a publicly held entity, and worked with numerous other companies in the biotechnology industry as well as various other industries. Prior to this, Mr. Selhorn worked at Grant Thornton LLP, a public accounting firm, from October 2003 to July 2013, most recently in the role of Senior Manager, Transaction Advisory Services. Mr. Selhorn received his BSBA, Accounting and Finance from Georgetown University.
This person is not in any offices
Aytu BioScience
2 followers
Aytu BioPharma (NASDAQ: AYTU) is a specialty pharmaceutical company with a growing commercial portfolio of prescription therapeutics and consumer health products, including ADHD and pediatrics medications. Their evolution has been driven by strategic in-licensing, acquisition-based transactions and organic product growth. As they continue on this trajectory, they are building a complimentary therapeutic development pipeline that will address significant unmet needs.